SUMMARY Factor VIII R:Ag was measured serially in 42 patients who had intracranial haemorrhage. It was found that the factor decreased or remained static in the 24 patients who improved (p < 0O025), while it increased in the 18 who died (p < 0 0005). It is suggested that this factor can be used as a prognostic parameter to predict the outcome after intracranial haemorrhage.
Factor VIII circulates in the plasma as a complex composed of two components: factor VIII:C, which has the clotting activity, and factor VIII R:Ag, or von Willebrand's Factor, which is responsible for platelet adhesiveness to subendothelium.' Factor VIII R:Ag is synthesised mainly by endothelial cells and megakaryocytes.2-5 It is released from endothelial cells into the blood stream in response to certain stimuli, such as venous occlusion, exercise, infusion of adrenaline, nicotinic acid, vasopressin and 1-deamino-8-D arginine vasopressin (DDAVP).67 A rise in factor VIII R:Ag level is noticed after pneumoencephalography and electro-shock which is not blocked by beta blockers.8 9 It is also seen in glomerulonephritis, pre-eclampsia and in limb ischaemia in diabetes. o Since all parameters used to assess the prognosis in intracranial haemorrhage are either clinical or radiological, " and since there are no chemically measurable substances to achieve this, we decided to study the value of factor VIII R:Ag in this respect. The aim was to determine the changes of factor VIII R:Ag in cases of intracranial haemorrhage and to study prospectively whether it can be used as a prognostic factor in the determination of the outcome in patients afflected with such haemorrhage, and to do so as early as possible in the course of the disease.
Patients and methods
This study was prospective and concerned 62 patients who were admitted to the Jordan University Hospital (JUH) in the years 1983, 1984 and 1985. All patients with suspected CNS bleeding were subjected to computed tomography (CT) on admission, and those with proven CNS bleeding were admitted to the study. All patients were examined by the three authors daily until discharge or death, and all relevant information was thus recorded.
On admission a full "coagulation screen" was performed on each patient, and consisted of: (1) Bleeding time by the Ivy method using simplate-II device (General Diagnostics, New Jersey, USA), (2) Prothrombin time and partial thromboplastin time (Orthodiagnostics, Raritan, New Jersey, USA), (3) Plasma fibrinogen by electro-immunoassay using commercial antisera (Hoechst, Frankfurt/Main, West Germany), and (4) Manual platelet count. In addition the plasma was tested on the first and third days following admission for factor VIII R:Ag and factor VIII:C as previously described.l2
Results
Sixty two patients were studied, 20 of whom were excluded: ten because of underlying haemostatic defect (table 1), four because of disseminated intra- 
